These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11342342

  • 1. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, Eling WM, De Witte T.
    Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
    [Abstract] [Full Text] [Related]

  • 2. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 3. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
    van Horssen PJ, van Oosterhout YV, Evers S, Backus HH, van Oijen MG, Bongaerts R, de Witte T, Preijers FW.
    Leukemia; 1999 Feb 04; 13(2):241-9. PubMed ID: 10025898
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Int J Cancer; 1990 Mar 15; 45(3):481-5. PubMed ID: 2307538
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I.
    Int J Cancer; 1999 Mar 31; 81(1):148-55. PubMed ID: 10077166
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V.
    Blood; 1993 Nov 01; 82(9):2624-33. PubMed ID: 8219217
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.